Elekta AB (publ) - Asset Resilience Ratio
Elekta AB (publ) (EKTA-B) has an Asset Resilience Ratio of 9.18% as of January 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Elekta AB (publ) strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2025)
This chart shows how Elekta AB (publ)'s Asset Resilience Ratio has changed over time. See debt-free asset ratio of Elekta AB (publ) to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Elekta AB (publ)'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Elekta AB (publ) (EKTA-B) total market value.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr2.54 Billion | 9.18% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr2.54 Billion | 9.18% |
Asset Resilience Insights
- Limited Liquidity: Elekta AB (publ) maintains only 9.18% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Elekta AB (publ) Industry Peers by Asset Resilience Ratio
Compare Elekta AB (publ)'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SHE:002223 |
Medical Devices | 0.84% |
|
Novocure Ltd
NASDAQ:NVCR |
Medical Devices | 43.72% |
|
Shanghai MicroPort EV MedTech Co. Ltd. A
SHG:688351 |
Medical Devices | 49.23% |
|
Jafron Biomedical Co Ltd
SHE:300529 |
Medical Devices | 39.15% |
|
Anteris Technologies Global Corp
AU:AVR |
Medical Devices | 33.27% |
|
Beijing Chunlizhengda Medical Instruments Co Ltd
SHG:688236 |
Medical Devices | 25.01% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 9.96% |
|
EBR Systems Inc
AU:EBR |
Medical Devices | 54.70% |
Annual Asset Resilience Ratio for Elekta AB (publ) (2012–2025)
The table below shows the annual Asset Resilience Ratio data for Elekta AB (publ).
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-04-30 | 10.20% | Skr2.96 Billion ≈ $318.01 Million |
Skr28.98 Billion ≈ $3.12 Billion |
+3.24pp |
| 2024-04-30 | 6.96% | Skr2.19 Billion ≈ $235.14 Million |
Skr31.41 Billion ≈ $3.38 Billion |
-0.64pp |
| 2023-04-30 | 7.60% | Skr2.25 Billion ≈ $242.14 Million |
Skr29.61 Billion ≈ $3.19 Billion |
-4.10pp |
| 2022-04-30 | 11.70% | Skr3.08 Billion ≈ $331.13 Million |
Skr26.30 Billion ≈ $2.83 Billion |
-1.07pp |
| 2021-04-30 | 12.77% | Skr3.17 Billion ≈ $341.36 Million |
Skr24.84 Billion ≈ $2.67 Billion |
-5.63pp |
| 2020-04-30 | 18.40% | Skr5.23 Billion ≈ $562.62 Million |
Skr28.41 Billion ≈ $3.06 Billion |
+8.42pp |
| 2019-04-30 | 9.98% | Skr2.40 Billion ≈ $258.49 Million |
Skr24.06 Billion ≈ $2.59 Billion |
+1.81pp |
| 2018-04-30 | 8.17% | Skr1.83 Billion ≈ $197.37 Million |
Skr22.46 Billion ≈ $2.42 Billion |
+2.09pp |
| 2017-04-30 | 6.08% | Skr1.27 Billion ≈ $137.00 Million |
Skr20.95 Billion ≈ $2.25 Billion |
+7.87pp |
| 2016-04-30 | -1.80% | Skr-349.00 Million ≈ $-37.56 Million |
Skr19.44 Billion ≈ $2.09 Billion |
-0.12pp |
| 2015-04-30 | -1.67% | Skr-354.00 Million ≈ $-38.10 Million |
Skr21.18 Billion ≈ $2.28 Billion |
-45.02pp |
| 2012-04-30 | 43.35% | Skr6.60 Billion ≈ $710.70 Million |
Skr15.23 Billion ≈ $1.64 Billion |
-- |
About Elekta AB (publ)
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers linear accelerator and radiation therapy products comprising Elekta Unity for anatomy-specific MR imaging; Elekta Evo that delivers offline and online adaptive radiation therapy; Elekta Versa … Read more